 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||
 |
 |
 |
 |
 |
 |
|
|||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||
 |
 |
 |
 |
 |
|
||||||||||||||||
|
|
Commercialization: Invenio Therapeutics A fifth company associated with The Center for Stem Cell and Regenerative Medicine began in June 2007. Invenio Therapeutics was founded by Dr. William Tse, M.D. University Hospitals Case Medical Center, Dr. David Wald, M.D. and Mr. Michael Gilkey, M.B.A, M.S. The initial idea for the technology was submitted by Dr. Wald on August 2, 2005 and submitted for a provisional patent on June 12, 2007. The intellectual property for this start-up consists of drug compounds that terminally differentiate leukemia cells so that they no longer have the ability to divide and replicate. Once these cells die, the disease is cured. The founders have submitted a Phase I SBIR to the NIH to begin preclinical animal studies in preparation for an IND. In parallel with this proposal other funding opportunities to move this technology forward will be pursued including a CSCRM Pilot Grant for 2008. For more information on Invenio Therapeutics, Inc. please contact David Wald at david.wald@case.edu. |
